Marvel Biotechnology Begins cGMP Manufacturing of Lead Candidate

Marvel Biotechnology has reported a milestone in the development of its lead compound MB-204, entering into a current good manufacturing process (cGMP) manufacturing agreement with Zhejiang Ausun Pharmaceutical. The partnership is for the supply of Marvel’s lead asset MB-204 for toxicology studies and clinical trials. MB-204 has potential application for the treatment of depression and anxiety, Alzheimer's, ADHD and non-neurological diseases such as cancer and non-alcoholic steatohepatitis.

Ausun was chosen and the agreement entered into as a result of an extensive Request for Proposal (RFP) process and negotiations undertaken by Marvel Biotechnology for the pilot manufacturing of its lead compound MB-204. The company said Ausun possesses the expertise in process development and custom manufacturing of active pharmaceutical ingredients (APIs), intermediates and formulated products; and will develop the chemical process and manufacture of Marvel's MB-204 API formulation.

"This is a major science milestone event for the company as we work to achieve and develop our lead asset MB-204 for clinical testing and commercialization," said Mark Williams, president and chief science officer, Marvel. "This program has now commenced and follows after the completion of our reverse take-over and amalgamation transaction with our partners at Alphanco, and the recommencement of trading on the TSXV last week as Marvel Biosciences Corp. We look forward to updating the market on our progress and the lead asset, MB-204."